Conditional relative survival among patients with chronic lymphocytic leukaemia: A population‐based study in the Netherlands

Lina van der Straten(Erasmus MC), Avinash G. Dinmohamed(Netherlands Comprehensive Cancer Organisation), Mark‐David Levin(Albert Schweitzer Hospital), Otto Visser(Netherlands Comprehensive Cancer Organisation), Arnon P. Kater(Amsterdam University Medical Centers), Eduardus F. M. Posthuma(Leiden University Medical Center), Jeanette K. Doorduijn(Erasmus MC Cancer Institute)
eJHaem
December 20, 2021
10.1002/jha2.368
Cited by 9

Related Papers

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568
Impact of Introducing Stereotactic Lung Radiotherapy for Elderly Patients With Stage I Non–Small-Cell Lung Cancer: A Population-Based Time-Trend Analysis
|Journal of Clinical Oncology|2010|478
Early-stage lung cancer in elderly patients: A population-based study of changes in treatment patterns and survival in the Netherlands
|Annals of Oncology|2012|173